{ rtf1 ansi ansicpg1252 deff0 deflang1033{ fonttbl{ f0 fswiss fcharset0 Arial;}} { * generator Msftedit;} viewkind4 uc1 pard f0 fs21 The primary goal of the WC-ACSR is to acquire, store, and equitably distribute tumor and biological fluids par from patients with HIV-associated malignancies and to actively participate within the structure of the national par ACSR program.
par Specific Aims : par 1)Establish an organizational and structural model that will support the primary purpose of the par National ACSR through contributions in leadership, and active participation in all of the ACSR par activities and developmental programs par The WC-ACSR is centered at San Francisco General Hospital and has major specimen referral sites at par UCSF, DSC, UCLA, University of Hawaii and San Diego. The WC-ACSR PI, Dr McGrath has been the par chairman of the ACSR steering committee for all 14 years of its existence and is committed to the par advancement of the overall goals of the ACSR going forward. The WC-ACSR will participate in all of the par CODCC defined governance and outreach committees, work to advance the ACSR database to comply with par CABIG regulatory requirements for the future and comply with all criteria for success as defined in the ACSR par MOO and by the NCI best practices program for biorepositories. The WC-ACSR has been successful in par adding value to the ACSR national program by providing specimens to successful applicants to the ACSR. par Unique aspects of the WC-ACSR collection program: 1) Source of the largest multi-site autopsy specimen par collections, with >12,000 specimens in the frozen tissue bank (70 cases of AIDS lymphoma, 44 of KS with par many sets of other controls and non-AIDS defining cancers) and > 8000 specimens in the fixed fixed tissue par bank; 2) Real time sources of fresh blood and tissues from patients with AIDS and AIDS related cancers; 3) par Access to specimen collections including an 80,000 specimen collection from the SF gay men's health study par on KS and HHV8 and multisite autopsies of non-AIDS defining cancers in HIV patients 4) Provision to par investigators of the most widely used HHV8 positive cell line (BCBL1) in the world and 5) Leading the par development program for creation of valuable ACSR derived research products such as TMA generation par with associated tissue DMA available for novel molecular studies of AIDS related cancers. par 2)To innovatively support AIDS-malignancy translational research through acquisition and par distribution of relevant biospecimens par The WC-ACSR has added novel programs to obtain specimens form HIV infected patients who are par experiencing the """"""""next wave"""""""" of cancers, those non-AIDS defining. Several blood and tissue acquisition par programs have been initiated to achieve these goals. Overall, the WC-ACSR will work within the overall par ACSR to ensure that investigators receive the best materials for their research goals, and to evolve the par collection and specimens characterization processes to allow the ACSR applicants to have access to par specimens from the entire AIDS epidemic time frame preserved in a manner appropriate for evaluation by par state of the art technologies. fs20 par par }

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRRB-9 (J2))
Program Officer
Liddell Huppi, Rebecca
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
Internal Medicine/Medicine
Schools of Medicine
San Francisco
United States
Zip Code
Lee, Guinevere Q; Bangsberg, David R; Mo, Theresa et al. (2017) Prevalence and clinical impacts of HIV-1 intersubtype recombinants in Uganda revealed by near-full-genome population and deep sequencing approaches. AIDS 31:2345-2354
Lee, Guinevere Q; McCluskey, Suzanne; Boum 2nd, Yap et al. (2017) Brief Report: Should Abacavir Be a First-Line Alternative for Adults With HIV in Sub-Saharan Africa? J Acquir Immune Defic Syndr 76:188-192
Lee, Guinevere Q; Lachowski, Chris; Cai, Eric et al. (2016) Non-R5-tropic HIV-1 in subtype A1 and D infections were associated with lower pretherapy CD4+ cell count but not with PI/(N)NRTI therapy outcomes in Mbarara, Uganda. AIDS 30:1781-8
Matthews, Lynn T; Ribaudo, Heather B; Kaida, Angela et al. (2016) HIV-Infected Ugandan Women on Antiretroviral Therapy Maintain HIV-1 RNA Suppression Across Periconception, Pregnancy, and Postpartum Periods. J Acquir Immune Defic Syndr 71:399-406
Nieves, Christina I; Kaida, Angela; Seage 3rd, George R et al. (2015) The influence of partnership on contraceptive use among HIV-infected women accessing antiretroviral therapy in rural Uganda. Contraception 92:152-9
Chan, Brian T; Weiser, Sheri D; Boum, Yap et al. (2015) Declining prevalence of probable depression among patients presenting for antiretroviral therapy in rural Uganda: the role of early treatment initiation. AIDS Behav 19:19-26
Kane, Eleanor; Skibola, Christine F; Bracci, Paige M et al. (2015) Non-Hodgkin Lymphoma, Body Mass Index, and Cytokine Polymorphisms: A Pooled Analysis from the InterLymph Consortium. Cancer Epidemiol Biomarkers Prev 24:1061-70
Byakwaga, Helen; Hunt, Peter W; Laker-Oketta, Miriam et al. (2015) The Kynurenine Pathway of Tryptophan Catabolism and AIDS-Associated Kaposi Sarcoma in Africa. J Acquir Immune Defic Syndr 70:296-303
Chan, Brian T; Weiser, Sheri D; Boum, Yap et al. (2015) Persistent HIV-related stigma in rural Uganda during a period of increasing HIV incidence despite treatment expansion. AIDS 29:83-90
Lee, Guinevere Q; Bangsberg, David R; Muzoora, Conrad et al. (2014) Prevalence and virologic consequences of transmitted HIV-1 drug resistance in Uganda. AIDS Res Hum Retroviruses 30:896-906

Showing the most recent 10 out of 51 publications